Siglec-1 on monocytes is a potential risk marker for monitoring disease severity in coronary artery disease.
Clin Biochem
; 42(10-11): 1057-63, 2009 Jul.
Article
em En
| MEDLINE
| ID: mdl-19285973
ABSTRACT
OBJECTIVES:
Siglec-1 has long been considered as an important biomarker of the activation of monocyte/macrophage and a type I interferon-specific imprint, but its role in atherosclerosis has not been elucidated.METHODS:
We examined the expression of Siglec-1 by flow cytometry and RT-PCR in 83 CAD patients and 38 healthy controls. In addition, the levels of serum lipids, Gensini score, hs-CRP and homocysteine were determined.RESULTS:
The transcriptional and protein levels of Siglec-1 on monocytes in CAD patients were significantly increased compared with healthy controls [3.17 versus 1.0, P<0.01; (11.5+/-3.9)% versus (1.8+/-2.0)%, P<0.01], but the increased Siglec-1 had no correlation with the level of native serum lipids. Interestingly, the expression of Siglec-1 was positively correlated with Gensini score (r=0.338, P=0.015), hs-CRP (r=0.316, P=0.016) and homocysteine level (r=0.224, P=0.042).CONCLUSION:
Siglec-1 may be considered as a potential non-invasive indicator for monitoring disease severity and a biomarker for predicting the relative risk of cardiovascular events.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença da Artéria Coronariana
/
Glicoproteínas de Membrana
/
Monócitos
/
Receptores Imunológicos
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article